Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system
Hematol., Transfus. Cell Ther. (Impr.)
; 46(1): 58-66, Jan.-Mar. 2024. tab, graf
Article
в En
| LILACS
| ID: biblio-1557889
Ответственная библиотека:
BR408.1
Локализация: BR408.1
ABSTRACT
Abstract Introduction Chimeric Antigen Receptor (CAR) T cells have tremendous potentials for cancer treatment; however, various challenges impede their universal use. These restrictions include the poor function of T cells in tumor microenvironments, the shortage of tumor-specific antigens and, finally, the high cost and time-consuming process, as well as the poor scalability of the method. Creative gene-editing tools have addressed each of these limitations and introduced next generation products for cell therapy. The clustered regularly interspaced short palindromic repeats-associated endonuclease 9 (CRISPR/Cas9) system has triggered a revolution in biology fields, as it has a great capacity for genetic manipulation. Method In this review, we considered the latest development of CRISPR/Cas9 methods for the chimeric antigen receptor T cell (CAR T)-based immunotherapy. Results The ability of the CRISPR/Cas9 system to generate the universal CAR T cells and also potent T cells that are persistent against exhaustion and inhibition was explored. Conclusion:
We explained CRISPR delivery methods, as well as addressing safety concerns related to the use of the CRISPR/Cas9 system and their potential solutions.Key words
Полный текст:
1
База данных:
LILACS
Основная тема:
Neoplasms
Язык:
En
Журнал:
Hematol., Transfus. Cell Ther. (Impr.)
Тематика журнала:
Hematologia
/
TransfusÆo de Sangue
Год:
2024
Тип:
Article